- Home
- PHAR vs CAC Comparison
PHAR vs CAC Comparison
Compare PHAR & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CAC
- Stock Information
- Founded
- PHAR 1988
- CAC 1875
- Country
- PHAR Netherlands
- CAC United States
- Employees
- PHAR N/A
- CAC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CAC Major Banks
- Sector
- PHAR Health Care
- CAC Finance
- Exchange
- PHAR Nasdaq
- CAC Nasdaq
- Market Cap
- PHAR 731.1M
- CAC N/A
- IPO Year
- PHAR N/A
- CAC 1997
- Fundamental
- Price
- PHAR $9.88
- CAC $43.03
- Analyst Decision
- PHAR Strong Buy
- CAC Hold
- Analyst Count
- PHAR 3
- CAC 3
- Target Price
- PHAR $30.00
- CAC $47.33
- AVG Volume (30 Days)
- PHAR 4.3K
- CAC 55.2K
- Earning Date
- PHAR 07-31-2025
- CAC 07-29-2025
- Dividend Yield
- PHAR N/A
- CAC 3.89%
- EPS Growth
- PHAR N/A
- CAC 2.54
- EPS
- PHAR N/A
- CAC 3.09
- Revenue
- PHAR $320,708,000.00
- CAC $184,324,000.00
- Revenue This Year
- PHAR $13.31
- CAC $40.83
- Revenue Next Year
- PHAR $7.68
- CAC $5.29
- P/E Ratio
- PHAR N/A
- CAC $14.00
- Revenue Growth
- PHAR 24.13
- CAC 13.26
- 52 Week Low
- PHAR $6.65
- CAC $31.79
- 52 Week High
- PHAR $12.61
- CAC $50.07
- Technical
- Relative Strength Index (RSI)
- PHAR 40.64
- CAC 68.35
- Support Level
- PHAR $10.46
- CAC $38.11
- Resistance Level
- PHAR $11.49
- CAC $40.92
- Average True Range (ATR)
- PHAR 0.31
- CAC 0.99
- MACD
- PHAR -0.16
- CAC 0.44
- Stochastic Oscillator
- PHAR 0.00
- CAC 88.50
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.